Anteris Technologies Global (NASDAQ:AVR) Shares Up 12.6% – Should You Buy?

Anteris Technologies Global Corp. (NASDAQ:AVR)’s stock price traded up 12.6% during trading on Thursday . The stock traded as high as $9.71 and last traded at $10.0750. 176,960 shares changed hands during mid-day trading, a decline of 84% from the average session volume of 1,133,399 shares. The stock had previously closed at $8.95.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Wall Street Zen upgraded shares of Anteris Technologies Global from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Barclays raised their price objective on shares of Anteris Technologies Global from $17.00 to $18.00 and gave the stock an “overweight” rating in a report on Friday, May 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anteris Technologies Global in a report on Friday, May 29th. Wells Fargo & Company initiated coverage on shares of Anteris Technologies Global in a report on Wednesday, March 11th. They set an “overweight” rating and a $16.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $15.00 price objective on shares of Anteris Technologies Global in a report on Friday, March 27th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Anteris Technologies Global Price Performance

The stock’s 50 day moving average is $6.66 and its 200-day moving average is $5.79. The company has a market capitalization of $937.87 million, a P/E ratio of -4.37 and a beta of 1.78.

Anteris Technologies Global (NASDAQ:AVR) last announced its earnings results on Tuesday, May 12th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.01). Anteris Technologies Global had a negative net margin of 5,148.78% and a negative return on equity of 124.76%. The business had revenue of $0.49 million for the quarter, compared to the consensus estimate of $0.77 million. During the same period in the prior year, the business posted ($0.61) EPS. On average, equities research analysts anticipate that Anteris Technologies Global Corp. will post -1.14 EPS for the current year.

Hedge Funds Weigh In On Anteris Technologies Global

Institutional investors and hedge funds have recently made changes to their positions in the business. Deutsche Bank AG boosted its stake in shares of Anteris Technologies Global by 8.1% during the 4th quarter. Deutsche Bank AG now owns 28,865 shares of the company’s stock worth $144,000 after acquiring an additional 2,171 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Anteris Technologies Global by 35.7% during the 3rd quarter. Bank of America Corp DE now owns 10,631 shares of the company’s stock worth $48,000 after acquiring an additional 2,798 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Anteris Technologies Global by 76.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,536 shares of the company’s stock worth $29,000 after acquiring an additional 2,841 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Anteris Technologies Global by 35.2% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,744 shares of the company’s stock worth $45,000 after acquiring an additional 3,055 shares during the last quarter. Finally, Barclays PLC lifted its stake in shares of Anteris Technologies Global by 3.0% during the 4th quarter. Barclays PLC now owns 148,128 shares of the company’s stock valued at $739,000 after buying an additional 4,289 shares in the last quarter.

Anteris Technologies Global Company Profile

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.